tiprankstipranks
GENinCode Highlights Growth and Study on Heart Disease
Company Announcements

GENinCode Highlights Growth and Study on Heart Disease

GENinCode UK Ltd. (GB:GENI) has released an update.

Don't Miss Our Christmas Offers:

GENinCode UK Ltd. has published a study highlighting the impact of lifestyle and genetic factors on coronary heart disease, showcasing that individuals with high polygenic risk can significantly reduce their risk through lifestyle changes. The company’s CARDIO inCode-Score® is gaining adoption in leading U.S. healthcare institutions, contributing to its projected revenue growth of up to 39% for 2024. GENinCode continues to expand its market presence, marking its first U.S. revenues and strengthening its position in the cardiovascular disease prevention sector.

For further insights into GB:GENI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskGENinCode Expands ROCA Test Access Across Switzerland
TipRanks UK Auto-Generated NewsdeskGENinCode Reports Strong Growth and US Market Entry
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App